KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to -$7.7 million.

  • Arbutus Biopharma's Income towards Parent Company rose 6080.52% to -$7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.3 million, marking a year-over-year increase of 4489.46%. This contributed to the annual value of -$69.9 million for FY2024, which is 402.06% up from last year.
  • Per Arbutus Biopharma's latest filing, its Income towards Parent Company stood at -$7.7 million for Q3 2025, which was up 6080.52% from $2.5 million recorded in Q2 2025.
  • In the past 5 years, Arbutus Biopharma's Income towards Parent Company ranged from a high of $2.5 million in Q2 2025 and a low of -$24.5 million during Q1 2025
  • Moreover, its 5-year median value for Income towards Parent Company was -$17.9 million (2024), whereas its average is -$16.7 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first tumbled by 3762.33% in 2021, then surged by 11264.4% in 2025.
  • Arbutus Biopharma's Income towards Parent Company (Quarter) stood at -$21.3 million in 2021, then fell by 2.87% to -$21.9 million in 2022, then rose by 11.95% to -$19.3 million in 2023, then soared by 35.28% to -$12.5 million in 2024, then surged by 38.16% to -$7.7 million in 2025.
  • Its last three reported values are -$7.7 million in Q3 2025, $2.5 million for Q2 2025, and -$24.5 million during Q1 2025.